Study of XL092 + Atezolizumab vs Regorafenib in Participants With Metastatic Colorectal Cancer
NCT05425940 · STELLAR-303 Phase 3Active, not recruiting
- Lead sponsor
- Exelixis (Industry)
- Enrollment
- 901 (actual)
- Start date
- 7 Sep 2022
- Primary completion
- 16 Jun 2026 (actual)
- Study completion
- 31 Jan 2027
- Last update posted
- 17 Jul 2026
Design
- Study type
- Interventional
- Primary purpose
- Treatment
- Allocation
- Randomized
- Intervention model
- Parallel
- Masking
- None
- Arms
- 2
Interventions
- XL092 Drug
- Atezolizumab Drug
- Regorafenib Drug
Conditions and primary outcome
- Colorectal Cancer
Primary outcome
Overall Survival (OS) of XL092 + Atezolizumab Versus Regorafenib in All Randomized Participants (Up to 32 months); Overall Survival (OS) of XL092 + Atezolizumab Versus Regorafenib in Randomized Non-Liver Metastases (NLM) Participants (Up to 32 months)
Posted results on ClinicalTrials.gov
Results posted on ClinicalTrials.gov: No
Results from company and journal sources
No editor-confirmed results are on record for this study.
Publications
2 on PubMedZanzalintinib plus atezolizumab versus regorafenib in refractory colorectal cancer (STELLAR-303): a randomised, open-label, phase 3 trial.
Lancet (London, England) · 2025 Nov 15
PubMed 41130252 (opens in a new tab)DOI 10.1016/S0140-6736(25)02025-2 (opens in a new tab)
STELLAR-303: randomized phase III study of zanzalintinib + atezolizumab in previously treated metastatic colorectal cancer.
Future oncology (London, England) · 2024
PubMed 39041200 (opens in a new tab)DOI 10.1080/14796694.2024.2352276 (opens in a new tab)
Citations from PubMed, U.S. National Library of Medicine; abstracts are not stored. A publication lists this study’s NCT number and may be a review that cites many studies.
CT-VCA trial quality
About CT-VCALoading CT-VCA scores…
Data integrity
Compare what the registry, company releases, FDA documents and publications say about this study.
Drugs on HealthTrade
Source
- NCT05425940 on ClinicalTrials.gov (opens in a new tab) Licence: public-domain. Read
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Listing a study does not mean NLM has evaluated it.
Nothing on this page is medical or investment advice.